Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data vTv Therapeutics Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
0.63
0.29
12.4
2.76
6.41
4.01
2.02
0
1.02
0
Research and development
45
39.6
23
15.1
11
13.3
12.4
13.6
11.5
17.9
General and administrative
9.91
11.3
9.22
8.54
7.25
12.3
12.2
11.9
13.7
14.9
Operating expenses
55.7
51
32.3
23.7
18.3
25.7
24.6
25.5
25.2
32.8
Operating income
-55
-50.7
-19.8
-20.9
-11.9
-21.7
-22.5
-25.5
-24.2
-32.8
Interest expense
0.4
3.09
3.29
1.83
0.69
0.01
0.02
0.01
0
Interest income
0.09
0.12
0.06
0.05
0.01
0
0.35
0.47
1.57
1.87
Other non-operating income
-0.02
0.05
0
0
2.45
-3.62
-1.5
Pre-tax income
-55.4
-53.8
-23.6
-21.8
-12.8
-17.6
-24.9
-26
-22.6
-31.1
Income tax
0
0.8
0.2
0.1
0
0.12
0.2
0
0.1
0
Net income to minority interests
-39
-38.5
-15.9
-8.89
-4.3
-4.74
-5.91
-5.72
-4.24
-4.11
Net income
-16.4
-16.1
-7.91
-13
-8.5
-13
-19.2
-20.3
-18.5
-27
EBITDA
-54.8
-50.5
-19.6
-20.9
-11.8
-21.6
-22.4
-25.4
-24.1
-32.8
Balance sheet
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
51.5
11.8
1.68
1.78
5.75
13.4
12.1
9.45
36.7
88.9
Receivables
0
8
0
0.01
0.16
0.06
0.17
0.1
0.06
Other current assets
0.61
0.44
0.67
0.81
0.94
2.05
2.54
1.04
0.18
0.22
Total current assets
52.1
20.4
3.47
2.84
7.22
15.6
27.1
10.7
38.1
89.9
Property, plant and equipment
0.44
0.28
0.07
0.46
0.37
0.28
0.21
0.12
0.03
Lease right-of-use assets
0.54
0.48
0.4
0.35
0.24
0.13
Long-term investments
2.48
2.48
2.48
6.73
9.17
5.59
0
Other non-current assets
1.93
0.15
0.01
Total assets
54.5
27.9
8.56
9.27
14.8
25.5
33.2
11
38.3
89.9
Accounts payable
3.06
2.27
2.9
2.23
1.93
1.88
2.46
4.08
0.94
1.13
Deferred revenue
0.02
8.76
1.75
0.03
0.03
0.04
0.02
0.02
0
Short-term debt
0.22
0.14
0.08
0.26
Total current liabilities
11.4
26.9
18.8
13.4
6.39
8.5
7.71
10.6
5.2
6.64
Long-term debt
11.1
15.3
6.33
0
0
0
0
Lease liabilities
0.83
0.68
0.49
0.34
0.17
0
Other non-current liabilities
0.43
0.29
0.26
0.26
0.05
Total liabilities
22.9
47.5
28.9
18.1
11
10.3
27.4
29.6
24
25.5
Total debt
11.1
15.1
5.04
Paid-in capital
124
128
151
184
209
238
255
256
312
391
Retained earnings
-215
-279
-234
-234
-290
-249
-266
-281
-300
-327
Shareholders' equity
-90.9
-151
-82.9
-49
-80.1
-9.74
-10.7
-24.7
12.2
64.4
Minority interests
0
2.1
0
Total equity
-90.9
-151
-82.9
-49
-80.1
-9.74
-10.7
-24.7
14.3
64.4
Total liabilities and equity
54.5
27.9
8.56
9.27
14.8
25.5
33.2
11
38.3
89.9
Cash flow statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-55.4
-54.6
-23.8
-21.9
-12.8
-17.7
-25.1
-26
-22.7
-31.1
Depreciation and amortization
0.27
0.2
0.22
0.04
0.09
0.09
0.09
0.09
0.09
0.02
Stock-based compensation
2.64
3.65
2.68
1.52
1.01
2.36
1.27
1.58
2.76
3.78
Change in receivables
0.07
-8
8
-0.01
-0.15
0.1
-0.12
0.07
0.04
Change in payables
4.79
2.45
-6.2
-0.62
-1
1.83
-0.86
2.93
-5.22
1.53
Cash from operations
-48.2
-44.6
-26.9
-23
-18
-19.3
-16
-19.1
-25.3
-25.3
Capital expenditures
-0.09
-0.06
-0.01
-0.07
0
0
-0.02
0
0
Cash from investing
-0.08
-0.03
0.01
0.24
0
0
-0.02
4.4
0
0
Debt repaid
-0.03
Stock issued
21.5
5.44
14.4
26.8
0
0
2.46
0
Cash from financing
11.8
7.5
16.6
22.9
19.5
27
14.8
12
52.6
77.4
Net change in cash
-36.5
-37.1
-10.2
0.09
1.47
7.67
-1.29
-2.68
27.3
52.2
Free cash flow
-48.3
-44.6
-26.9
-23.1
-18
-19.3
-16
-19.1
-25.3
Interest paid
0.24
2.06
2.28
1.3
0.62
0.01
0.02
0.01
0
0.01
Income taxes paid
1
0.1
0
0.12
0.2
0
0.1
0
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $30.21 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Operating margin
-25.1%
Operating income / revenue.
EBITDA margin
-25.1%
EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin
-17.4%
Pre-tax income / revenue.
Net margin
-12.9%
Net income / revenue.
Operating cash flow margin
-45.5%
Cash from operations / revenue.
Return on equity (ROE)
-6.0%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-5.4%
Net income / average total assets.
R&D / revenue
77.8%
Research and development expense / revenue.
Stock-based pay / revenue
14.0%
Stock-based compensation (from the cash flow statement) / revenue.
D&A / revenue
0.0%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
-100.0%
Revenue vs the same period a year earlier. Only from a positive base.
Book value growth, 1y
428.2%
Book value vs the same period a year earlier. Only from a positive base.
Total assets growth, 1y
134.9%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
39.3%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
43.5%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
12.5x
Current assets / current liabilities.
Quick ratio
12.3x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
12.3x
(Cash + short-term investments) / current liabilities.
Market cap + total debt - cash - short-term investments.
P/S
3.24x
Market cap / revenue.
P/B
1.52x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
1.52x
Market cap / tangible book value, when positive.
EV/Sales
0.89x
Enterprise value / revenue.
Earnings yield
-4.0%
Net income / market cap (the inverse of P/E).
What was vTv Therapeutics Inc.'s revenue in fiscal 2025?
vTv Therapeutics Inc. reported revenue of $0.0 for fiscal 2025, 100% lower than the year before.
Was vTv Therapeutics Inc. profitable in fiscal 2025?
No. It reported a net loss of $27.0M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.